Relative Bioavailability of Pimasertib in Cancer Patients

Pimasertib capsule administration at a single dose of 60 milligram (mg) orally on Day 1 in Part A.

Pimasertib tablet administration at a single dose of 60 mg orally on Day 3 in Part A.

Pimasertib tablet administration at a single dose of 60 mg orally on Day 1 in Part A.

Pimasertib capsule administration at a single dose of 60 mg orally on Day 3 in Part A.

Subjects completing Part A to receive pimasertib capsule at a dose of 60 mg orally twice daily in cycles of 21 days each in Part B and trial extension phase until disease progression, intolerable toxicity, subject withdrawal, loss to follow-up or death.